Business context and reporting period
Filing identity: The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended March 31, 2021 (ticker ACRX), not a filing naming Talphera, Inc. AcelRx was a specialty pharmaceutical company developing and commercializing therapies for medically supervised settings. Its principal marketed product was DSUVIA in the U.S.; Zalviso was marketed in Europe by Grünenthal through May 12, 2021. DZUVEO was approved in Europe but had no commercialization partner disclosed.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Total revenue | $511,000 | $386,000 | Up 32% |
| Product sales | $451,000 | $274,000 | Up 65%; DSUVIA $181,000, Zalviso $270,000 |
| Operating expenses | $9.653 million | $16.234 million | Down 41% |
| Operating loss | $9.142 million | $15.848 million | Loss narrowed |
| Net loss | $8.956 million | $15.925 million | Loss narrowed 44%; loss per share $0.08 vs. $0.20 |
| Net cash used in operations | $9.708 million | $14.364 million | Cash burn declined |
- Cost of goods sold was $1.040 million against $451,000 of product sales, implying a negative product gross margin of approximately 131% (gross loss $589,000). The filing attributes lower total COGS year over year mainly to reduced indirect manufacturing costs.
- Cash, cash equivalents and short-term investments totaled $67.345 million at March 31, 2021, up from $42.886 million at year-end. Current assets were $71.315 million and current liabilities $15.544 million.
- Financing cash flow was $34.222 million, chiefly reflecting $36.360 million of net equity proceeds; investing cash flow was an outflow of $17.425 million, mainly due to investment purchases.
- Oxford debt accrued to $19.1 million, including current and long-term portions, and had a scheduled maturity of June 1, 2023. A separate $87.6 million long-term liability relates to monetized future royalties; it is not presented as conventional Oxford loan debt.
- Total liabilities were $114.659 million, exceeding total assets of $87.347 million; stockholders’ deficit was $27.312 million. Accumulated deficit was $447.441 million.
Material changes versus the prior comparable period
- Revenue rose primarily because European Zalviso sales increased to $270,000 from $119,000; U.S. DSUVIA sales grew more modestly, to $181,000 from $155,000.
- Operating expenses fell by $6.581 million. SG&A declined $5.667 million, including lower personnel, commercialization, business development and facilities costs. R&D fell $443,000; COGS fell $471,000.
- Shares outstanding increased from 98.8 million at December 31, 2020 to 119.1 million at March 31, 2021. The company issued 16.675 million shares in a public offering and sold approximately 3.0 million shares through its ATM program during the quarter.
- Cash and investments increased substantially, mainly due to equity financing, while operating cash use remained significant.
Outlook, commentary, risks and unusual items
- Management expected existing capital resources to fund operations for at least the next 12 months, but stated they would not fund the company until it could generate sufficient revenue to sustain operations. The company expected significant losses to continue and anticipated needing additional capital over the longer term.
- COVID-19 restrictions limited sales-force access to hospitals and surgery centers, delayed formulary decisions and elective procedures, and weighed on near-term DSUVIA sales. Management expected access to improve in the second half of 2021, but this was uncertain.
- The installed high-volume DSUVIA packaging line was expected to receive FDA approval in 2022; approval and the anticipated subsequent reduction in COGS were not assured. A five-year Catalent commercial supply agreement was disclosed as a subsequent event.
- Grünenthal’s Zalviso collaboration ended, and European rights reverted to AcelRx on May 12, 2021. The company had not disclosed a replacement license partner and remained obligated to use commercially reasonable efforts to negotiate one. The royalty monetization limits the company’s share of future European royalties until the contractual cap is reached.
- The FDA issued a February 11, 2021 warning letter concerning DSUVIA promotional materials, citing allegedly misleading risk and efficacy claims. AcelRx responded and held a meeting with FDA staff; it said it could not assure that its response would resolve the concerns.
- The timing of a U.S. Zalviso NDA resubmission depended partly on FDA opioid approval guidance. FDA questions could include how inadvertent dispensing of tablets is counted in device error rates, potentially requiring additional work or limiting approval.
- Unusual item: a $522,000 gain from terminating the company’s prior headquarters lease reduced reported expenses. Inventory impairment charges were approximately $100,000 in Q1 2021, mainly for Zalviso components.
- Major risks include continued operating losses and financing needs, product adoption and reimbursement, opioid-related regulation and litigation exposure, manufacturing and supply dependence, and compliance with DSUVIA’s REMS restrictions. Management reported disclosure controls effective and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether DSUVIA sales, facility access and formulary adoption improved after the quarter, and whether the COVID-related outlook proved accurate.
- Progress on the FDA warning-letter response and any subsequent promotional restrictions or enforcement actions.
- FDA approval timing and costs for the high-volume packaging line, and whether it delivered the projected manufacturing-cost reductions.
- Whether AcelRx secured a replacement Zalviso European partner and the resulting economics after SWK’s royalty rights.
- Cash burn, financing needs, dilution, Oxford debt service and covenant compliance; the stated 12-month liquidity outlook was not a path to long-term self-funding.
- Any subsequent developments in Zalviso’s U.S. NDA resubmission, FDA device-error concerns and potential additional regulatory requirements.